Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6304-6309

  Kyle, Alastair H ^a,b   Huxham, Lynsey A ^a   Chiam, Aaron S J ^a   Sim, David H ^a   Minchinton, Andrew I ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b Canadian Institutes of Health Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BROXURIDINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; MITOXANTRONE;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL CULTURE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SCREENING; DRUG TISSUE LEVEL; FLUORESCENCE; HUMAN; HUMAN CELL; METHODOLOGY; PRIORITY JOURNAL; SOLID TUMOR; TISSUE DISTRIBUTION;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; HCT116 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MITOXANTRONE; SPECTROMETRY, FLUORESCENCE; TUMOR CELLS, CULTURED;

EID: 4344578280     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1099     Document Type: Article

References (32)

1. Rubin P, Casarett G. Microcirculation of tumors. Part I: anatomy, function and necrosis. Clin Radiol 1966;17:220-9.
2. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
3. Brown JM. Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br J Radiol 1979;52:650-6.
4. Durand RE, LePard NE. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncologica 1995;34:317-23.
5. Chaplin DJ, Durand RE, Olive PL. Acute hypoxia in tumour: Implications for modifiers of radiation effects. In J Radiat Oncol Biol Phys 1986;12:1279-82.
6. Minchinton AI, Durand RE, Chaplin DJ. Intermittent blood flow in the KHT sarcoma: flow cytometry studies using Hoechst 33342. Br J Cancer 1990;62:195-200.
7. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
8. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 1997;26:71-90.
9. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-84.
10. Cowan DSM, Hicks KO, Wilson WR. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer 1996;74:S28-31.
11. Minchinton AI, Wendt KR, Clow KA, Fryer KH. Multilayers of cells growing on a permeable support: an in vitro tumour model. Acta Oncologica 1997;36:13-6.
12. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (Wash. DC) 1988;240:177-84.
13. Kyle AH, Minchinton AI. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 1999;43:213-20.
14. Hicks KO, Ohms SJ, van Zijl PL, et al. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer 1997;76: 894-903.
15. Kyle AH, Huxham LA, Baker JH, Burston HE, Minchinton AI. Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent. Cancer Res 2003;63: 5707-11.
16. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 2003;66:1207-18.
17. Di Marco A, Casazza AM, Dasdia T, et al. Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety. Chem Biol Interact 1977;19:291-302.
18. Demant EJ, Friche E. Kinetics of anthracycline accumulation in multidrug-resistant tumor cells: relationship to drug lipophilicity and serum albumin binding. Biochem Pharmacol 1998;56:1209-17.
19. Frezard F, Garnier-Suillerot A. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur J Biochem 1991;196:483-91.
20. Cantoni O, Sestili P, Cattabeni F, Geroni C, Giuliani F. Comparative effects of doxorubicin and 4′-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line. Cancer Chemother Pharmacol 1990;27:47-51.
21. Burns CP, Haugstad BN, Mossman CJ, North JA, Ingraham LM. Membrane lipid alteration: effect on cellular uptake of mitoxantrone. Lipids 1988;23:393-7.
22. Demant EJ, Friche E. Equilibrium binding of anthracycline cytostatics to serum albumin and small unilamellar phospholipid vesicles as measured by gel filtration. Biochem Pharmacol 1998;55:27-32.
23. Mulder HS, Dekker H, Pinedo HM, Lankelma J. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Biochem Pharmacol 1995;50:967-74.
24. Frezard F. Garnier-Suillerot A. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei. Biochim Biophys Acta 1990;1036:121-7.
25. Danesi R, Innocenti F, Fogli S, et al. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br J Clin Pharmacol 2002;53:508-18.
26. Rentsch KM, Schwendener RA, Pestalozzi BC, et al. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Eur J Clin Pharmacol 1998;54:83-9.
27. Pea F, Russo D, Michieli M, et al. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Cancer Chemother Pharmacol 2000;46:279-86.
28. Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003;14:239-46.
29. Chassany O, Urien S, Claudepierre P, Bastian G, Tillement JP. Binding of anthracycline derivatives to human serum lipoproteins. Anticancer Res 1994;14: 2353-5.
30. Chassany O, Urien S, Claudepierre P, Bastian G, Tillement JP. Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol 1996;38: 571-3.
31. Durand RE. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother Pharmacol 1990;26:198-204.
32. Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 1994;13:121-38.